东西方肝癌的分析比较.ppt

东西方肝癌的分析比较.pptGeographic and ethnic factors become important in the era of molecular targeted therapy for cancers
Asian (n=342)
Non-Asian (n=1350)
Proportion surviving
Time (months)






0
2
4
6
8
10
12
14
16
0
2
4
6
8
10
12
14
16
Gefitinib
Placebo
Importance of Ethnicity for MTA ─ the lessons of ISEL trial
EGFR mutation rates in each subgroup
Study
Centre
No. of patients
AdenoCa
(+BAC) (%)
M (%)
F (%)
Smokers (%)
n-smokers (%)
Taiwan1
NTUH
62
49
25
61
29
56
Taiwan2
VGH-T
37

52
72
44
69
Korea3
Seoul NU
90
21
9
33
13
26
Japan4
NCC Tokyo
66
61
53
69
35
68
Japan5
Aichi CCH
59
64
44
70
42
71
HK6
Chinese U
72
32
—
—
—
—
China7
Pek UMCH
76



—
—
Italy8*
U Chieti
375
10
6
30
7
25
Shih et al, IJC 2005
Chou et al, CCR 2005
Han et al, JCO 2005
Takano et al, JCO 2005
*only AdenoCa
Mitsudomi et al, JCO 2005
Lung et al, PAACR 2005
Mu et al, CCR 2005
Machetti et al, JCO 2005
Liver Cancer in the World
Ferlay J et al. IARC Press, 2001.
Men (396,364) / Women (165,972)
North
America (%)
/
Central & South
America (%)
/
Africa (%)
/
Europe (%)
/
Asia (%)
/
Oceania (%)
/
Geographic differences in the results of clinical trials for advanced HCC
SorafenibMedian: weeks ( mo)(95% CI: , )
Survival Probability
Weeks
Hazard ratio (S/P): (95% CI: , )
P=*
PlaceboMedian: weeks ( mo) (95% CI: , )

0



0
80
8
16
24
32
40
48
56
64
72
0
274
241
205
161
108
67
38
12
0
Patients at risk Sorafenib:
0
276
224
179
126
78
47
25
7
2
Placebo:
299
303
Phase III SHARP TrialOverall survival (Intention-to-treat)
Llovet J et al, N Engl J Med. 2008 Jul 24;359(4):378-90
( mo)
Comparison of Tx(-) Control Arms
P’t
No
Median
OS
PVT
TNM
Stage IV
Okuda
Stage III
ECOG
III